Related Experiment Video
Updated: Jul 13, 2026
Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the
Madhuri Bhasin1, Muzhou Wu, Stella E Tsirka
1Genetics, Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, NY 11794-8651, USA. bhasin@pharm.stonybrook.edu <bhasin@pharm.stonybrook.edu>
Background:
Myelin Oligodendrocyte Glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) is the most commonly used mouse model for multiple sclerosis (MS). During the of progression of EAE, microglia, the immunocompetent cells of the brain, become activated and accumulate around demyelinated lesions. Microglial activation is mediated by the extracellular protease tissue Plasminogen Activator (tPA), and mice lacking tPA display altered EAE progression. In this study, we have used pharmacological inhibitors and stimulators of microglial/macrophage activation to examine the temporal requirement for microglial activation in EAE progression and to determine whether such approaches might potentially be of therapeutic value.
Results:
Intervention using the tripeptide macrophage/microglia inhibitory factor MIF (TKP) and the tetrapeptide macrophage/microglial stimulator tuftsin (TKPR) attenuated EAE symptoms and revealed that the timing of macrophage/microglial activation is critical for the clinical outcome of EAE. We show that the disease progression can potentially be manipulated favorably at early stages by altering the timing of microglial activation, which in turn alters the systemic immune response to favor upregulation of T helper cell 2 genes that promote recovery from EAE.
Conclusion:
Preventative and therapeutic modulation of macrophage/microglial activity significantly alters the outcome of EAE at symptomatic stages. Specific molecular targets have been identified that represent potential avenues of exploration for the treatment and prevention of MS.
Insights
Modulating microglial activation timing in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS), can favorably alter disease progression. Early intervention using specific inhibitors or stimulators promotes recovery by shifting the immune response.
Area of Science:
- Neuroimmunology
- Experimental models of neuroinflammation
Background:
- Myelin Oligodendrocyte Glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) is a key mouse model for multiple sclerosis (MS).
- Microglial activation, mediated by tissue Plasminogen Activator (tPA), is crucial during EAE progression, with microglia accumulating at demyelinated lesions.
- Mice lacking tPA exhibit altered EAE progression, highlighting the role of microglial activation in disease pathogenesis.
Purpose of the Study:
- To investigate the temporal requirements of microglial/macrophage activation in EAE progression.
- To evaluate the therapeutic potential of modulating microglial/macrophage activation in EAE.
Main Methods:
- Utilized pharmacological inhibitors and stimulators of microglial/macrophage activation.
- Examined the effects of interventions on EAE symptom progression and clinical outcomes.
- Analyzed changes in the systemic immune response, including T helper cell gene expression.
Main Results:
- Intervention with macrophage/microglia inhibitory factor (MIF) and stimulator (tuftsin) attenuated EAE symptoms.
- The timing of microglial activation critically influences the clinical outcome of EAE.
- Early-stage modulation of microglial activation favorably altered disease progression and promoted recovery by upregulating T helper cell 2 genes.
Conclusions:
- Preventative and therapeutic modulation of macrophage/microglial activity significantly impacts EAE outcomes.
- Targeting microglial activity presents potential therapeutic strategies for MS treatment and prevention.
- Identified specific molecular targets for future exploration in MS therapy.
